Meghalaya Magazine

X-linked hypophosphatemia Market: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight

 Breaking News
  • No posts were found

X-linked hypophosphatemia Market: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight

October 14
04:35 2021
X-linked hypophosphatemia Market: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight
X-linked hypophosphatemia Market

X-linked hypophosphatemia is a hereditary renal phosphate-wasting disorder characterized by hypophosphatemia, rickets and/or osteomalacia, and diminished growth. Phosphate levels are low because phosphate is abnormally processed in the kidneys, which causes a loss of phosphate in the urine (phosphate wasting) and leads to soft, weak bones (rickets). XLH is usually diagnosed in childhood. Features include bowed or bent legs, short stature, bone pain, and severe dental pain. XLH is the most common form of hereditary hypophosphatemic rickets.

 

DelveInsight’s X Linked Hypophosphatemia Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the X Linked Hypophosphatemia, historical and forecasted epidemiology as well as the X Linked Hypophosphatemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some facts of X Linked Hypophosphatemia Market Report are:

  • According to study conducted by He ́le`ne et al., titled “Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms”, the estimated prevalence of X-linked hypophosphatemia was 4.8 per 100,000.
  • As per Endocrine Society, the Food and Drug Administration (FDA) estimates that XLH affects about 3,000 children and 12,000 adults in the United States
  • According to Phosphodiabetes E.V. Netzwerk Information Austausch, estimates that X-linked hypophosphatemia (XLH) is the most common form of vitamin D-resistant rickets and, with a prevalence of 4.8 cases per 100,000 individuals, is considered a rare disease.
  • The study by Riancho et al., titled “Osteomalacia and rickets” estimates that the prevalence of Hypophosphatemic rickets linked to the X chromosome due to a mutation in the PHEX gene is around 5 per 100,000.

 

Request for Sample Report: https://www.delveinsight.com/sample-request/x-linked-hypophosphatemia-market

 

Scope of X Linked Hypophosphatemia Market Report are:

  • The report covers the descriptive overview of X Linked Hypophosphatemia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the X Linked Hypophosphatemia epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for X Linked Hypophosphatemia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of X Linked Hypophosphatemia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global X Linked Hypophosphatemia market

 

View Report: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market

 

Some of X Linked Hypophosphatemia Companies are:

  • Ultragenyx
  • Validus Pharmaceuticals
  • Prospec-Tany Technogene Ltd
  • Merck KGaA
  • Zeria Pharmaceutical Co., Ltd
  • Smith & Nephew
  • Narang Medical Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • And Many Others

 

X Linked Hypophosphatemia Therapies are:

  • Burosumab
  • Crysvita
  • And Many Others

 

Table of Contents:

1. Key Insights

2. Executive Summary of X Linked Hypophosphatemia

3. Competitive Intelligence Analysis for X Linked Hypophosphatemia

4. X Linked Hypophosphatemia: Market Overview at a Glance

4.1. X Linked Hypophosphatemia Total Market Share (%) Distribution in 2018

4.2. X Linked Hypophosphatemia Total Market Share (%) Distribution in 2030

5. X Linked Hypophosphatemia: Disease Background and Overview

6. Patient Journey

7. X Linked Hypophosphatemia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. X Linked Hypophosphatemia Treatment and Management

8.2. X Linked Hypophosphatemia Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of X Linked Hypophosphatemia Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. X Linked Hypophosphatemia: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of X Linked Hypophosphatemia

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market